Sotevtamab

DB19120InvestigationalProtein Based Therapies

Sotevtamab is under investigation in clinical trial NCT06225843 (Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis).

Mechanism: Pharmacologically active on Clusterin
Curator reviewed
Also known as: Immunoglobulin g2, anti-(human clusterin .beta.-chain) (human-mus musculus monoclonal ab-16b5 .gamma.2-chain), disulfide with human-mus musculus monoclonal ab-16b5 .kappa.-chain, dimer
Code names: AB-16B5

Resolves to

Compound

UNIIYQ3YJK67AFCAS2411526-47-9

Targets

P10909CLU

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sotevtamab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account